In the process of finding out if my oral cancer is back. Imaging is not showing focal point so only option is a...
Ask Navis about your situation
This answer is general. Get one about your specific case — no signup, answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Question asked:
In the process of finding out if my oral cancer is back. Imaging is not showing focal point so only option is a blind biopsy. What other tests can I do ?
I'm sorry you're going through this uncertainty. Let me help you understand what diagnostic options exist for suspected oral cancer recurrence when imaging isn't showing a clear focal point.
Understanding Your Situation
When imaging (CT, MRI, PET) doesn't identify a specific lesion but clinical suspicion remains high, doctors need to confirm whether cancer is present. This is a common challenge in oral cancer surveillance.
Diagnostic Tests Beyond Blind Biopsy
Here are additional or complementary approaches that may be worth discussing with your oncology team:
1. Enhanced Imaging Techniques
- PET-CT with higher resolution protocols - Can sometimes detect metabolic activity even without a visible mass
- MRI with diffusion-weighted imaging (DWI) - Particularly sensitive for detecting early mucosal changes
- Narrow-band imaging (NBI) endoscopy - Uses special light wavelengths to highlight abnormal tissue patterns in the oral cavity
2. Tissue Sampling Approaches
- Brush biopsy or exfoliative cytology - Less invasive than needle biopsy; samples cells from suspicious areas
- Narrow-band imaging-guided biopsy - Combines visualization with targeted sampling
- Multiple site biopsies - If a specific area is suspected based on clinical exam
3. Biomarker/Molecular Testing
- HPV testing - If your original cancer was HPV-related, this can help guide surveillance
- Liquid biopsy approaches - Emerging technology; ask if your center offers circulating tumor DNA (ctDNA) testing
4. Enhanced Clinical Examination
- Toluidine blue staining - Highlights abnormal tissue for targeted biopsy
- Autofluorescence imaging - Shows tissue changes not visible to the naked eye
Questions to Ask Your Oncology Team
- "Have we done PET-CT or MRI with DWI recently? Could these be repeated with enhanced protocols?"
- "Is narrow-band imaging endoscopy available to help identify the exact biopsy site?"
- "Would brush biopsy or exfoliative cytology be appropriate before proceeding to blind biopsy?"
- "Are there any liquid biopsy or circulating tumor DNA tests available at our center?"
- "If we proceed with biopsy, would you use imaging guidance or special visualization techniques to target the most suspicious areas?"
Important Context
According to NCCN Guidelines for Head and Neck Cancers, surveillance for recurrence typically involves:
- Clinical examination (most important)
- Imaging as clinically indicated
- Tissue diagnosis when recurrence is suspected
The American Cancer Society emphasizes that while blind biopsy can be performed, targeted approaches using visualization techniques improve diagnostic accuracy.
Next Steps
Your care team knows your complete clinical picture—your original tumor location, pathology, treatment history, and current symptoms. They can determine which combination of tests makes sense for YOUR specific case.
This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.
Ask Navis about your case
That answer is general. Ask about your specific situation — no signup, answered right here.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Have your records handy? Upload them for a deeper, personalized analysis →
Related Questions
Just finished the perspective therapeutics VMT-a-NET phase 1b dosing trial These are the results of my latest PET...
TL;DR: Your latest PET scan shows your cancer is stable—the tumors in your liver are about the same size as before, no new tumors appeared, and the tr
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
We are in the UK royal marsden. It is kind of hopeless or how to say? Is there any immunetherapy worth to pursue or...
TL;DR: Diffuse midline gliomas DMGs with H3K27M are very challenging, but immunotherapy and targeted approaches are actively being researched—the Roya
It is my daughter she completed 6 weeks of radio and tmz now she is on 3rd cycle of tmz 200mg. We are doing low meth...
TL;DR: Your daughter's treatment plan radiation + TMZ chemotherapy is standard for diffuse midline glioma, and her biomarkers MGMT methylated, EGFR A2